1.18
6.31%
0.07
Pre-mercato:
1.19
0.01
+0.85%
Precedente Chiudi:
$1.11
Aprire:
$1.13
Volume 24 ore:
1.62M
Relative Volume:
1.24
Capitalizzazione di mercato:
$345.59M
Reddito:
$6.23M
Utile/perdita netta:
$-95.90M
Rapporto P/E:
-3.0256
EPS:
-0.39
Flusso di cassa netto:
$-68.47M
1 W Prestazione:
+8.76%
1M Prestazione:
+54.73%
6M Prestazione:
-25.79%
1 anno Prestazione:
-7.81%
Precigen Inc Stock (PGEN) Company Profile
Nome
Precigen Inc
Settore
Industria
Telefono
301-556-9900
Indirizzo
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Confronta PGEN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.18 | 345.59M | 6.23M | -95.90M | -68.47M | -0.39 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-03-22 | Downgrade | JP Morgan | Neutral → Underweight |
2023-05-23 | Iniziato | JP Morgan | Neutral |
2022-11-18 | Iniziato | Cantor Fitzgerald | Overweight |
2021-02-25 | Iniziato | Stifel | Buy |
2021-02-22 | Iniziato | Wells Fargo | Overweight |
2021-02-18 | Iniziato | B. Riley Securities | Buy |
2020-05-08 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Precigen Inc Borsa (PGEN) Ultime notizie
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Precigen, Inc. Regains Compliance with Nasdaq Listing Rules - Defense World
Precigen shares rebound above Nasdaq minimum bid price - MSN
Precigen shares rebound above Nasdaq minimum bid price By Investing.com - Investing.com Australia
Should You Invest in Precigen (PGEN)? - MSN
Jane Street Group LLC Reduces Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment By Investing.com - Investing.com Australia
Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment - Investing.com India
Precigen's (PGEN) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Precigen to Present Plans for Realizing Commercial Vision for PR - GuruFocus.com
Precigen Files BLA for Breakthrough RRP Treatment PRGN-2012, Targets 27,000 US Patients - StockTitan
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
Precigen CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Barclays PLC Acquires 124,141 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Geode Capital Management LLC - Defense World
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - MSN
Investors Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - Defense World
Traders Purchase High Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat
Exploring 3 Prominent High Growth Tech Stocks In The United States - Simply Wall St
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally - MSN
Precigen, Inc. (NASDAQ:PGEN) Shares Acquired by State Street Corp - Defense World
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail - Asianet Newsable
Stifel Financial Corp Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen's SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com Australia
Precigen, Inc. announced that it has received $79 million in funding - Marketscreener.com
Precigen’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Precigen's SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment - Benzinga
Precigen Completes Submission of BLA with Request for Priority R - GuruFocus.com
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis – Company AnnouncementFT.com - Financial Times
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - Defense World
Precigen announces $79 million private placement offering of convertible preferred stock - MSN
Precigen secures $79 million in private placement By Investing.com - Investing.com Canada
Precigen, Inc. Enters into Asset Acquisition Agreement with Innovator 21, LLC - Defense World
Precigen, Inc. announced that it expects to receive $79 million in funding - Marketscreener.com
Precigen Announces $79.0 Million Private Placement Offering of C - GuruFocus.com
Precigen secures $79 million in private placement - Investing.com
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock - Nasdaq
Nnovator 21, LLC acquired Certain assets, including intellectual property rights and royalty rights, related to FCX-007 from Precigen, Inc. for $8.5 million. - Marketscreener.com
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by HighTower Advisors LLC - Defense World
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Analysts Update Their Estimates For Precigen Inc - Stocks Register
Precigen Inc Azioni (PGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):